Morgan Stanley expects Zepbound to rake in $2.2 billion in sales in 2024, according to a note released after the drug's approval in November
The specific gaps are: No human phase I or II trial for BPC-157 in any indication No published combination study in any model No pharmacokinetic data on subcutaneous GHK-Cu in humans No standardized outcome measures for the soft-tissue repair indications practitioners most commonly target The American College of Sports Medicine's 2023 position statement on peptide therapeutics in sports medicine did not endorse BPC-157 or GHK-Cu for any clinical use, citing insufficient human data
The beneficial effects observed in those patients with early onset, low atherosclerotic burden include an improvement in plaque stability score in the brachiocephalic artery, attenuation of lipid deposits in the aorta, and reduction of weight gain
SAM Metabolism and Epigenetics Ulanovskaya et al
This material is designed for use in scientific research environments involving analytical method development, molecular characterization, stability assessment, validation studies, and other non-clinical laboratory investigations
The after-first-use window is particularly noteworthy
